Skip to main content

Market Overview

Amarin Reports 30th Patent for Vascepa


Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it now has 30 patents issued or allowed by the United States Patent and Trademark Office (USPTO) related to its flagship product, Vascepa^® (icosapent ethyl) capsules.

Amarin recently received Notices of Allowance for U.S. Patent Application Serial Numbers 13/777,398, 13/768,897, and 13/768,869, each titled "Stable Pharmaceutical Composition and Methods of Using Same." The scope of coverage related to Vascepa represented by these applications is the broadest allowed to date.


Related Articles (AMRN)

View Comments and Join the Discussion!

Posted-In: News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at